Literature DB >> 33131062

Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.

Bubu A Banini1,2, Divya P Kumar1,3, Hae-Ki Min1, Arun J Sanyal1, Sophie Cazanave1,4, Mulugeta Seneshaw1, Faridoddin Mirshahi1, Prasanna K Santhekadur3, Liangsu Wang5, Hong Ping Guan5, Abdul M Oseini1, Cristina Alonso6, Pierre Bedossa7, Srinivas V Koduru8,9.   

Abstract

BACKGROUND AND AIMS: The mechanisms by which the I148M mutant variant of the patatin-like phospholipase domain-containing 3 (PNPLA3I148M ) drives development of nonalcoholic steatohepatitis (NASH) are not known. The aim of this study was to obtain insights on mechanisms underlying PNPLA3I148M -induced acceleration of NASH. APPROACH AND
RESULTS: Hepatocyte-specific overexpression of empty vector (luciferase), human wild-type PNPLA3, or PNPLA3I148M was achieved using adeno-associated virus 8 in a diet-induced mouse model of nonalcoholic fatty liver disease followed by chow diet or high-fat Western diet with ad libitum administration of sugar in drinking water (WDSW) for 8 weeks. Under WDSW, PNPLA3I148M overexpression accelerated steatohepatitis with increased steatosis, inflammation ballooning, and fibrosis (P < 0.001 versus other groups for all). Silencing PNPLA3I148M after its initial overexpression abrogated these findings. PNPLA3I148M caused 22:6n3 docosahexanoic acid depletion and increased ceramides under WDSW in addition to increasing triglycerides and diglycerides, especially enriched with unsaturated fatty acids. It also increased oxidative stress and endoplasmic reticulum stress. Increased total ceramides was associated with signature of transducer and activator of transcription 3 (STAT3) activation with downstream activation of multiple immune-inflammatory pathways at a transcriptomic level by network analyses. Silencing PNPLA3I148M reversed STAT3 activation. Conditioned media from HepG2 cells overexpressing PNPLA3I148M increased procollagen mRNA expression in LX2 cells; this was abrogated by hepatocyte STAT3 inhibition.
CONCLUSIONS: Under WDSW, PNPLA3I148M overexpression promotes steatosis and NASH by metabolic reprogramming characterized by increased triglycerides and diglycerides, n3 polyunsaturated fatty acid depletion, and increased ceramides with resultant STAT3 phosphorylation and downstream inflammatory pathway activation driving increased stellate cell fibrogenic activity.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33131062      PMCID: PMC8046714          DOI: 10.1002/hep.31609

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

1.  PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.

Authors:  Elizabeth K Speliotes; Johannah L Butler; Cameron D Palmer; Benjamin F Voight; Joel N Hirschhorn
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  Degradation of Keap1 activates BH3-only proteins Bim and PUMA during hepatocyte lipoapoptosis.

Authors:  S C Cazanave; X Wang; H Zhou; M Rahmani; S Grant; D E Durrant; C D Klaassen; M Yamamoto; A J Sanyal
Journal:  Cell Death Differ       Date:  2014-04-25       Impact factor: 15.828

3.  Human thyroxine binding globulin (TBG) promoter directs efficient and sustaining transgene expression in liver-specific pattern.

Authors:  Zhonghai Yan; Hao Yan; Hailong Ou
Journal:  Gene       Date:  2012-07-20       Impact factor: 3.688

4.  Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids.

Authors:  Panu K Luukkonen; Auli Nick; Maarit Hölttä-Vuori; Christoph Thiele; Elina Isokuortti; Susanna Lallukka-Brück; You Zhou; Antti Hakkarainen; Nina Lundbom; Markku Peltonen; Marju Orho-Melander; Matej Orešič; Tuulia Hyötyläinen; Leanne Hodson; Elina Ikonen; Hannele Yki-Järvinen
Journal:  JCI Insight       Date:  2019-08-22

Review 5.  PUFAs: Structures, Metabolism and Functions.

Authors:  Anna Wiktorowska-Owczarek; Małgorzata Berezińska; Jerzy Z Nowak
Journal:  Adv Clin Exp Med       Date:  2015 Nov-Dec       Impact factor: 1.727

Review 6.  PNPLA3 I148M polymorphism and progressive liver disease.

Authors:  Paola Dongiovanni; Benedetta Donati; Roberta Fares; Rosa Lombardi; Rosellina Margherita Mancina; Stefano Romeo; Luca Valenti
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

Review 7.  Mechanisms of NAFLD development and therapeutic strategies.

Authors:  Scott L Friedman; Brent A Neuschwander-Tetri; Mary Rinella; Arun J Sanyal
Journal:  Nat Med       Date:  2018-07-02       Impact factor: 53.440

8.  The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease.

Authors:  Sophie Cazanave; Alexei Podtelezhnikov; Kristian Jensen; Mulugeta Seneshaw; Divya P Kumar; Hae-Ki Min; Prasanna K Santhekadur; Bubu Banini; Adolfo Gabriele Mauro; Abdul M Oseini; Robert Vincent; Keith Q Tanis; Andrea L Webber; Liangsu Wang; Pierre Bedossa; Faridoddin Mirshahi; Arun J Sanyal
Journal:  Sci Rep       Date:  2017-12-08       Impact factor: 4.379

9.  The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation.

Authors:  Soumik BasuRay; Eriks Smagris; Jonathan C Cohen; Helen H Hobbs
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

10.  Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.

Authors:  Daniel Lindén; Andrea Ahnmark; Piero Pingitore; Ester Ciociola; Ingela Ahlstedt; Anne-Christine Andréasson; Kavitha Sasidharan; Katja Madeyski-Bengtson; Magdalena Zurek; Rosellina M Mancina; Anna Lindblom; Mikael Bjursell; Gerhard Böttcher; Marcus Ståhlman; Mohammad Bohlooly-Y; William G Haynes; Björn Carlsson; Mark Graham; Richard Lee; Sue Murray; Luca Valenti; Sanjay Bhanot; Peter Åkerblad; Stefano Romeo
Journal:  Mol Metab       Date:  2019-02-05       Impact factor: 7.422

View more
  11 in total

1.  Drug Development in the Field of Sphinogolipid Metabolism.

Authors:  Zhibei Qu; Lu Zhou
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 2.  Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases.

Authors:  Rocío Gallego-Durán; Rocío Montero-Vallejo; Douglas Maya-Miles; Ana Lucena; Franz Martin; Javier Ampuero; Manuel Romero-Gómez
Journal:  Front Immunol       Date:  2021-11-24       Impact factor: 7.561

3.  KHK, PNPLA3 and PPAR as Novel Targets for the Anti-Steatotic Action of Bempedoic Acid.

Authors:  Ana Magdalena Velázquez; Roger Bentanachs; Aleix Sala-Vila; Iolanda Lázaro; Jose Rodríguez-Morató; Rosa María Sánchez; Juan Carlos Laguna; Núria Roglans; Marta Alegret
Journal:  Biomedicines       Date:  2022-06-27

4.  Glycyrrhetinic acid regulates impaired macrophage autophagic flux in the treatment of non-alcoholic fatty liver disease.

Authors:  Yadong Fan; Wenjin Dong; Ying Wang; Shan Zhu; Rundong Chai; Zhe Xu; Xiaoyu Zhang; Yiqi Yan; Long Yang; Yuhong Bian
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

5.  Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.

Authors:  Shenling Liao; Kang An; Zhi Liu; He He; Zhenmei An; Qiaoli Su; Shuangqing Li
Journal:  J Clin Lab Anal       Date:  2022-07-26       Impact factor: 3.124

6.  Oral-Gut Microbiome Analysis in Patients With Metabolic-Associated Fatty Liver Disease Having Different Tongue Image Feature.

Authors:  Chenxia Lu; Hui Zhu; Dan Zhao; Jia Zhang; Kai Yang; Yi Lv; Miao Peng; Xi Xu; Jingjing Huang; Zuoyu Shao; Mingzhong Xiao; Xiaodong Li
Journal:  Front Cell Infect Microbiol       Date:  2022-06-29       Impact factor: 6.073

Review 7.  Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma.

Authors:  Zelin Tian; Chen Xu; Peijun Yang; Zhibin Lin; Wenlong Wu; Wenjie Zhang; Jian Ding; Rui Ding; Xuan Zhang; Kefeng Dou
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

8.  Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.

Authors:  Elke Ericson; Linnéa Bergenholm; Anne-Christine Andréasson; Carly I Dix; Jane Knöchel; Sara F Hansson; Richard Lee; Jennifer Schumi; Madeleine Antonsson; Ola Fjellström; Patrik Nasr; Mathias Liljeblad; Björn Carlsson; Stergios Kechagias; Daniel Lindén; Mattias Ekstedt
Journal:  Hepatol Commun       Date:  2022-07-14

Review 9.  Sphingolipids in metabolic disease: The good, the bad, and the unknown.

Authors:  Christopher D Green; Michael Maceyka; L Ashley Cowart; Sarah Spiegel
Journal:  Cell Metab       Date:  2021-07-06       Impact factor: 31.373

Review 10.  Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis.

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-10       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.